Hormone Replacement Therapy and Dementia: The Biggest Study Yet Says It's Not One-Size-Fits-All

Researchers at the University of East Anglia and University of Exeter followed 183,450 postmenopausal women in the UK for an average of 13.3 years — the largest study of its kind to date. Published in Alzheimer's & Dementia, it found that women who used hormone replacement therapy (HRT) for at least a year had a 16% lower risk of developing Alzheimer's disease compared with women who never used it. But the headline number isn't the real story. The real story is who benefits — and it depends heavily on biology, genetics, and timing.

What They Found: The Numbers That Matter

• HRT users overall: ~10% lower risk of any dementia, 16% lower risk of Alzheimer's specifically

• Surgical menopause (ovaries removed): 26% lower risk of any dementia with HRT — the strongest benefit in the study

• Low lifetime estrogen exposure: 16% lower risk with HRT

• APOE4 carriers — stronger protection, even though they typically have fewer prevention options

• Timing matters: women who started HRT between ages 46–56 saw the greatest benefit — the critical window hypothesis

Why It Makes Sense: The Mechanisms

Two biological threads connect menopause to brain health. First, estrogen is brain fuel. Estrogen receptors are scattered throughout the brain, especially in regions vital for memory (hippocampus) and metabolism. When estrogen drops sharply at menopause, brain cells lose a key support signal — affecting energy use, inflammation control, and synaptic maintenance. Replacing that hormone may help keep those systems running.

Second, the APOE4 connection is amplified in women. The APOE4 gene variant is a known Alzheimer's risk factor, and its effect is stronger in women than men. Estrogen appears to interact with APOE pathways — which may explain why HRT showed extra benefit in carriers. Surgical menopause produces an abrupt, complete loss of ovarian estrogen — a bigger biological shock than natural menopause — which fits the 26% reduction figure.

The Critical Window: Why Timing Wins

The critical window hypothesis says estrogen replacement helps neurons most when started while the brain is still adjusting to the transition — roughly ages 46–56. Start much later, and the protection fades. This reframes the conversation: not whether to use HRT, but when — and for whom.

Important Caveats

• This is observational — it shows association, not proof

• HRT carries well-documented risks including certain cancers and blood clots depending on type, dose, and duration

• No randomized trial has confirmed this dementia-protective effect yet

Bottom Line

In the largest study of its kind, HRT was linked to a 16% lower risk of Alzheimer's — with far stronger benefits for women who had surgical menopause (26%), carried the APOE4 gene, or started HRT within the critical window. The takeaway isn't that everyone should take HRT. It's that the old one-size-fits-all approach to menopause treatment is collapsing in favor of personalized, biologically informed decisions about women's brain health.

Source: Alzheimer's & Dementia, 2026 — Squires, S., et al. — DOI: 10.1002/alz.71679 — Prospective cohort, n=183,450